Comment
Author: Admin | 2025-04-28
Other Severe Cutaneous Adverse Reactions (SCAR) are sometimes fatal. Discontinue ziprasidone hydrochloride if DRESS or SCAR are suspected. (5.5) Tardive Dyskinesia: May develop acutely or chronically. (5.6) Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. (5.7) Hyperglycemia and Diabetes Mellitus (DM): Monitor all patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients with DM risk factors should undergo blood glucose testing before and during treatment. (5.7) Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics. (5.7) Weight Gain: Weight gain has been reported. Monitor weight gain. (5.7) Rash: Discontinue in patients who develop a rash without an identified cause. (5.8) Orthostatic Hypotension: Use with caution in patients with known cardiovascular or cerebrovascular disease. (5.9) Leukopenia, Neutropenia, and Agranulocytosis has been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue ziprasidone hydrochloride at the first sign of a decline in WBC in the absence of other causative factors. (5.11) Seizures: Use cautiously in patients with a history of seizures or with conditions that lower seizure threshold. (5.12) Potential for Cognitive and Motor impairment: Patients should use caution when operating machinery. (5.13) Suicide: Closely supervise high-risk patients. (5.18) Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial,
Add Comment